[go: up one dir, main page]

Attal et al., 2010 - Google Patents

Lenalidomide maintenance after transplantation for myeloma.

Attal et al., 2010

Document ID
15517688104967576257
Author
Attal M
Cristini C
Marit G
Caillot D
Facon T
Hullin C
Moreau P
Mathiot C
Avet-Loiseau H
Harousseau J
Intergroupe Francophone du Myelome
Publication year
Publication venue
Journal of Clinical Oncology

External Links

Snippet

8018 Background: High-dose therapy with autologous stem cell transplantation (ASCT) is a standard treatment for myeloma patients. However, a residual disease (RD) responsible for relapse is always present. Effective maintenance treatment would be required. However …
Continue reading at ascopubs.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue

Similar Documents

Publication Publication Date Title
Attal et al. Lenalidomide maintenance after transplantation for myeloma.
Moreau et al. Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study.
Shustik et al. Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: a National Cancer Institute of Canada Clinical Trials Group Study: MY. 7
Madan et al. Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): implications for clinical trial design
Campos et al. Effect of guarana (Paullinia cupana) on fatigue in breast cancer patients undergoing systemic chemotherapy.
Rifkin et al. Updated results from a randomized multicenter trial of DVd vs VAd in patients with newly diagnosed multiple myeloma
Avet-Loiseau et al. Use of bortezomib to overcome the poor prognosis of t (4; 14), but not del (17p), in young patients with newly diagnosed multiple myeloma.
Mulherin et al. Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplants.
Huang et al. Tolerability of single agent nivolumab in cancer patients—A meta-analysis.
Blank et al. Cost differences among treatment options for patients with refractory myeloma previously treated with high-dose chemotherapy and autologous stem-cell transplantation: An analysis from the US and Swiss perspectives.
Davey et al. Prescription patterns and associated cost during periods of cancer drug stockouts in a resource-limited setting.
Roussel et al. Bortezomib and high-dose melphalan as conditioning regimen before transplantation for de novo multiple myeloma patients: Updated data of the IFM phase II study.
Mazumder et al. The effect of induction therapy with novel agents on stem cell mobilization in multiple myeloma
Remo et al. Hepatitis B virus screening in patients receiving intravenous chemotherapy.
Soper et al. Observation versus adjuvant radiation or chemotherapy in the management of stage I seminoma.
Mohty et al. The benefit of reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) as salvage treatment for relapsing multiple myeloma (MM)
Choi et al. A Retrospective Case Control Study to Identify Differences in Risk Factors for the Development of Renal Cell Carcinoma in Patients Treated at a Safety Net Hospital Compared to Patients Treated at a Private Hospital.
Parikh et al. Real world health and economic outcomes in patients with non-stem cell transplant (NSCT) multiple myeloma initially treated with lenalidomide and/or bortezomib-based regimens.
Azar et al. Outcomes of a late second autologous hematopoietic stem cell transplant compared to nontransplantation salvage therapy in relapsed multiple myeloma after upfront transplant.
Shah et al. Role of autologous stem cell transplant after induction therapy with bortezomib-lenolidomide or bortezomib-thalidomide in newly diagnosed multiple myeloma patients
Steensma et al. Clinical experience with different dosing schedules of decitabine in patients with myelodysplastic syndromes (MDS)
Stinchcombe et al. Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801
Aljitawi et al. The impact of HBO on early ALC recovery following high-dose therapy and autologous transplantation.
Fridrik Long term results for cladribine induction and interferon maintenance treatment in previous untreated follicular lymphoma
Paker et al. Posterior reversible encephalopathy syndrome in patients with cancer.